Eto S, Nukui Y, Tsumura M, Kashimada K, Mizoguchi Y, Utsumi T, et al. Neutralizing type I interferon autoantibodies in Japanese patients with severe COVID-19. J Clin Immunol. 2022;42:1360–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Solanich X, Rigo-Bonnin R, Gumucio V-D, Bastard P, Rosain J, Philippot Q, et al. Pre-existing autoantibodies neutralizing high concentrations of type I interferons in almost 10% of COVID-19 patients admitted to intensive care in Barcelona. J Clin Immunol. 2021;1733–44.

Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann H-H, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370:eabd4585.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chauvineau-Grenier A, Bastard P, Servajean A, Gervais A, Rosain J, Jouanguy E, et al. Autoantibodies neutralizing type I interferons in 20% of COVID-19 deaths in a French Hospital. J Clin Immunol. 2022;42:459–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arrestier R, Bastard P, Belmondo T, Voiriot G, Urbina T, Luyt C-E, et al. Auto-antibodies against type I IFNs in > 10% of critically ill COVID-19 patients: a prospective multicentre study. Ann Intensive Care. 2022;12:121.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bastard P, Gervais A, Voyer TL, Rosain J, Philippot Q, Michailidis E, et al. Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years old and account for ~ 20% of COVID-19 deaths. Sci Immunol. 2021;6(62). https://doi.org/10.1126/sciimmunol.abl4340.

Frasca F, Scordio M, Santinelli L, Gabriele L, Gandini O, Criniti A, et al. Anti-IFN-α/-ω neutralizing antibodies from COVID-19 patients correlate with downregulation of IFN response and laboratory biomarkers of disease severity. Eur J Immunol. 2022;52:1120–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goncalves D, Mezidi M, Bastard P, Perret M, Saker K, Fabien N, et al. Antibodies against type I interferon: detection and association with severe clinical outcome in COVID-19 patients. Clin Transl Immunol. 2021;10:e1327.

Article  CAS  Google Scholar 

Abers MS, Rosen LB, Delmonte OM, Shaw E, Bastard P, Imberti L, et al. Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID‐19. Immunol Cell Biol. 2021;99:917–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Busnadiego I, Abela IA, Frey PM, Hofmaenner DA, Scheier TC, Schuepbach RA, et al. Critically ill COVID-19 patients with neutralizing autoantibodies against type I interferons have increased risk of herpesvirus disease. PLoS Biol. 2022;20:e3001709.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Troya J, Bastard P, Planas-Serra L, Ryan P, Ruiz M, de Carranza M et al. Neutralizing autoantibodies to type I IFNs in > 10% of patients with severe COVID-19 pneumonia hospitalized in Madrid, Spain. J Clin Immunol. 2021;914–22.

Raadsen MP, Gharbharan A, Jordans CCE, Mykytyn AZ, Lamers MM, van den Doel PB, et al. Interferon-α2 auto-antibodies in convalescent plasma therapy for COVID-19. J Clin Immunol. 2022;42:232–9.

Akbil B, Meyer T, Stubbemann P, Thibeault C, Staudacher O, Niemeyer D, et al. Early and Rapid Identification of COVID-19 patients with neutralizing type I Interferon Auto-antibodies. J Clin Immunol. 2022;42:1111–29.

Koning R, Bastard P, Casanova J-L, Brouwer MC, van de Beek D. With the Amsterdam U.M.C. COVID-19 Biobank investigators. Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients. Intensive Care Med. 2021;47:704–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370:eabd4570.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Q, Bastard P, Bolze A, Jouanguy E, Zhang S-Y, Human Genetic COVID, Effort, et al. Life-threatening COVID-19: defective interferons unleash excessive inflammation. Med N Y N. 2020;1:14–20.

Google Scholar 

Luyt C-E, Bouadma L, Morris AC, Dhanani JA, Kollef M, Lipman J, et al. Pulmonary infections complicating ARDS. Intensive Care Med. 2020;46:2168–83.

Article  PubMed  PubMed Central  Google Scholar 

Luyt C-E, Sahnoun T, Gautier M, Vidal P, Burrel S, Pineton de Chambrun M, et al. Ventilator-associated pneumonia in patients with SARS-CoV-2-associated acute respiratory distress syndrome requiring ECMO: a retrospective cohort study. Ann Intensive Care. 2020;10:158.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance [Internet]. 2020 [cited 2022 May 23];25. https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.3.2000045.

de la Calle C, Lalueza A, Mancheño-Losa M, Maestro-de la Calle G, Lora-Tamayo J, Arrieta E, et al. Impact of viral load at admission on the development of respiratory failure in hospitalized patients with SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis. 2021;40:1209–16.

Article  PubMed  PubMed Central  Google Scholar 

Acute Respiratory Distress Syndrome. The Berlin Definition. JAMA [Internet]. 2012 [cited 2022 May 23];307. http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2012.5669

Manry J, Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, et al. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proc Natl Acad Sci U S A. 2022;119:e2200413119.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bastard P, Gervais A, Taniguchi M, Saare L, Särekannu K, Le Voyer T, et al. Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-abs in children. J Exp Med. 2024;221:e20231353.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Prost N, Bastard P, Arrestier R, Fourati S, Mahévas M, Burrel S, et al. Plasma exchange to rescue patients with autoantibodies against type I interferons and life-threatening COVID-19 pneumonia. J Clin Immunol. 2021;41:536–44.

Article  PubMed  PubMed Central  Google Scholar 

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 130:2620–9.

Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718–24.

Smith N, Possémé C, Bondet V, Sugrue J, Townsend L, Charbit B, et al. Defective activation and regulation of type I interferon immunity is associated with increasing COVID-19 severity. Nat Commun. 2022;13:7254.

Antonelli G, Giannelli G, Currenti M, Simeoni E, Del Vecchio S, Maggi F, et al. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy. Clin Exp Immunol. 1996;104:384–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet Lond Engl. 2003;362:1184–91.

Article  CAS  Google Scholar